KV Pharmaceutical (NYSE:KV.A) traded in a range yesterday that spanned from a low of $6.84 to a high of $8.19. Yesterday, the shares fell 12.88%, which took the trading range below the 3-day low of $7.89 on volume of 4.8 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean revision. Shares of KV Pharmaceutical should find initial support at their 50-day moving average (MA) of $6.52 and further support at their 200-day MA of $3.07. Look for the MA to provide resistance for a short-term rebound in the shares. SmarTrend is monitoring the recent change of momentum in KV Pharmaceutical. Please refer to our Company Overview for the results of our proprietary technical indicators that have been scanning shares of KV Pharmaceutical in search of a potential trend change. SmarTrend expects the share price to rebound toward the $7.89 resistance level. Afterwards, we expect it to move downward with its peers in the SmarTrend Drug Manufacturers- Generic industry.
Subscribe to:
Post Comments (Atom)
Superhit News
-
US health regulator USFDA has issued a warning letter to German drug firm Fresenius Kabi AG for lapses at its drug manufacturing fac...
-
Goods and Service Tax (GST) is high on the agenda for the new government and its rollout is a priority. GST will benefit the Indian pharma...
-
Rib-X Pharmaceuticals, Inc. announced today the signature of an exclusive worldwide research collaboration agreement and option for license ...
-
Physiomics: Reports difficult trading but highlights growing interest from big pharmaceutical groupsPhysiomics ( LON:PYC ) said that trading conditions were difficult in the six months ended 31 December 2010, but it believes it is in a be...
-
Hindusthan National Glass and Industries Ltd is expected to finalize a strategic overseas acquisition in the pharmaceuticals space in the n...
-
The Minister of State (Health and Family Welfare), Sh Ashwini Kumar Choubey through a written reply in the Lok Sabha informed about th...
-
The government is hoping to see the implementation of the track and trace system for domestic and export supply chain in another one y...
-
India's Central Drugs Standard Control Organization (CDSCO) has suspended the manufacturing of eye drops at the Chennai-based firm after...
-
Diclofenac injection is a painkiller which is manufactured by Themis Medicare Ltd and marketed by Novartis India under the brand name ...
-
Amylin Pharmaceuticals, Inc. AMLN +16.15% and Alkermes plc ALKS +4.61% today announced that the U.S. Food and Drug Administration (FDA) has ...
No comments:
Post a Comment